Anne Layne-Farrer is speaking on the panel titled “New Technologies, Business Models and Standards” during this conference.
For more information on this event, click here.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...